16305 36TH AVENUE N, MINNEAPOLIS, MN
Amended material disclosure
News, Material Contracts
Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Annual Report to Security Holders
Financial Results, Press Release
Changes in Board, Management or Compensation, Reg. FD
Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Amended Form D Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus